June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Association of oral montelukast with reduced odds of developing neovascular age-related macular degeneration
Irmak Karaca; Wataru Matsumiya; Amir Akhavanrezayat; Gunay Uludag; Cigdem Yasar; Azadeh Mobasserian; Jaclyn Joyce Hwang; Sherin Lajevardi; Brandon Chau Lam; Rubbia Afridi; Diana V Do; Yasir J Sepah; Quan Dong Nguyen
Author Affiliations & Notes
  • Irmak Karaca
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Wataru Matsumiya
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Amir Akhavanrezayat
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Gunay Uludag
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Cigdem Yasar
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Azadeh Mobasserian
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Jaclyn Joyce Hwang
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Sherin Lajevardi
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Brandon Chau Lam
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Rubbia Afridi
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Diana V Do
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Yasir J Sepah
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Quan Dong Nguyen
    Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Irmak Karaca, None; Wataru Matsumiya, None; Amir Akhavanrezayat, None; Gunay Uludag, None; Cigdem Yasar, None; Azadeh Mobasserian, None; Jaclyn Hwang, None; Sherin Lajevardi, None; Brandon Lam, None; Rubbia Afridi, None; Diana Do, Allergan (C), AsclepiX (C), Genentech (C), Genentech (F), Kodiak (C), Regeneron (C), Regeneron (F), Santen (C); Yasir Sepah, Astellos (F), Genentech (F), Optos (C), Optovue (F); Quan Nguyen, AbbVie (C), Bayer (C), Genentech (C), Mallinckrodt (C), Regeneron (C), Santen (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 275. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Association of oral montelukast with reduced odds of developing neovascular age-related macular degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Irmak Karaca, Wataru Matsumiya, Amir Akhavanrezayat, Gunay Uludag, Cigdem Yasar, Azadeh Mobasserian, Jaclyn Joyce Hwang, Sherin Lajevardi, Brandon Chau Lam, Rubbia Afridi, Diana V Do, Yasir J Sepah, Quan Dong Nguyen; Association of oral montelukast with reduced odds of developing neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2021;62(8):275.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : Given the role of chronic inflammation in the pathogenesis of age-related macular degeneration (AMD), montelukast might have a potential protective impact on the development of neovascular AMD (nAMD) through an anti-inflammatory effect including its selective antagonism for cysteinyl leukotriene receptor 1 (CysLTR1). The proposed case-control study aimed to evaluate the association of oral montelukast with reduced odds of nAMD development.

Methods : The index study was conducted using Institutional Cohort Finder tool, and included 1913 patients who were diagnosed as nAMD (ICD: H35.32 and 362.52) and visited the Byers Eye Institute at Stanford from 1991 to 2020, and 1913 age- and gender- matched control subjects without nAMD. The subjects were assessed for the presence of nAMD risk factors (e.g. smoking history, Caucasian race, hypertension, hyperlipidemia) and for the use of specific medications (e.g. oral montelukast, nasal or oral cromolyn [mast cell stabilizer], oral steroids, oral NSAIDs, oral H1-antihistamines). Then, the odds ratio (OR) calculations using multivariable conditional logistic regression analyses were performed in order to assess the effect of oral montelukast use on reducing the odds of nAMD development, adjusting for possible risk factors.

Results : A total of 47 (2.5%) nAMD cases were identified to have a history of oral montelukast use prior to nAMD diagnosis, compared to 84 (4.4%) controls (crude OR: 0.54, P=0.0001). In the multivariable analysis, montelukast usage was significantly associated with reduced odds of nAMD (adjusted OR: 0.57, P=0.004). On the other hand, Caucasian race (adjusted OR 1.52, P<0.0001), history of smoking (adjusted OR: 1.91, P<0.0001), and NSAIDs use (adjusted OR: 0.75, P=0.005) were found to have significant relationship with increased odds of nAMD.

Conclusions : The study results suggested that oral montelukast consumption is linked to reduced odds of nAMD development. Future prospective cohort studies is needed to validate these findings.

This is a 2021 ARVO Annual Meeting abstract.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept